OrganOx, spun out of the University of Oxford in 2008 and led by Oern R. Stuge, MD, MBA, develops the metra normothermic machine perfusion (NMP) platform to improve outcomes for patients with acute or chronic organ failure. The metra system is approved in the U.S., Europe, Canada and Australia and has been used in over 5,000 liver transplants to keep donor livers metabolically active, extend preservation times and enable functional assessment prior to transplant. The company is commercial stage and focuses on scaling its metra platform across global organ-technology markets. OrganOx says it will use new funding to expand operations and accelerate development efforts. Recent financings include a private placement first close and a primary/secondary equity raise intended to accelerate growth opportunities for the metra platform. OrganOx is an Oxford, UK–based commercial-stage organ medical technology company spun out of the University of Oxford in 2008 and led by Oern R. Stuge, MD, MBA, Executive Chairman. Its core product is the metra® normothermic machine perfusion (NMP) platform, approved in the U.S., Europe, Canada, and Australia, which keeps donor livers metabolically active outside the body for functional assessment prior to transplant. The metra® has been utilized in over 5,000 liver transplants to date, contributing to increased organ availability. The company also has an investigational metra® technology for kidney transplants that is expected to soon begin U.S. clinical trials and plans a first-in-human study with eGenesis combining metra® with genetically engineered porcine livers to support patients with acute-on-chronic liver failure. OrganOx recently closed a $142M equity financing and intends to use the funds to accelerate growth opportunities for its metra® platform in the global organ technology market. OrganOx develops metra, an automated normothermic machine perfusion (NMP) device that preserves donor livers in a functioning state for up to 24 hours and enables continuous monitoring and viability assessment. The metra platform provides surgeons with evidence-based data to decide whether to transplant donor organs and has enabled transplant of previously declined livers. The device is commercially available in Europe (CE Mark) and the United States. Since inception, OrganOx's NMP technology has supported over 2,500 liver transplants worldwide. The company was founded in 2008 by Professors Peter Friend and Constantin Coussios and is led by CEO Craig Marshall. OrganOx recently raised new growth funding to support its commercial and clinical expansion.

Total raised

$175M

Funding rounds

3

Latest round

Equity

Latest activity

Feb 2025